Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study.

Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR.

Ann Rheum Dis. 2013 Jul 13. doi: 10.1136/annrheumdis-2013-203407. [Epub ahead of print]

PMID:
23852763
[PubMed - as supplied by publisher]
2.

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.

Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR.

JAMA. 2013 Mar 6;309(9):887-95. doi: 10.1001/jama.2013.1099.

PMID:
23462785
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR.

JAMA. 2011 Dec 7;306(21):2331-9. doi: 10.1001/jama.2011.1692. Epub 2011 Nov 6.

PMID:
22056398
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study.

Winthrop KL, Chen L, Fraunfelder FW, Ku JH, Varley CD, Suhler E, Hills WL, Gattey D, Baddley JW, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Herrinton LJ, Fraunfelder FT, Saag KG, Lewis JD, Solomon DH, Curtis JR.

Am J Ophthalmol. 2013 Jan;155(1):183-189.e1. doi: 10.1016/j.ajo.2012.06.023. Epub 2012 Sep 8.

PMID:
22967869
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan.

Ke WM, Chen LS, Parng IM, Chen WW, On AW.

Int J Tuberc Lung Dis. 2013 Dec;17(12):1590-5. doi: 10.5588/ijtld.13.0368.

PMID:
24200274
[PubMed - indexed for MEDLINE]
6.

Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.

Kim SY, Schneeweiss S, Liu J, Solomon DH.

J Bone Miner Res. 2012 Apr;27(4):789-96. doi: 10.1002/jbmr.1489.

PMID:
22162140
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.

Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S.

Arthritis Rheum. 2006 Sep;54(9):2757-64. Erratum in: Arthritis Rheum. 2006 Oct;54(10):3134.

PMID:
16947774
[PubMed - indexed for MEDLINE]
Free Article
8.

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR.

Ann Rheum Dis. 2009 Feb;68(2):209-15. doi: 10.1136/ard.2007.087288. Epub 2008 Apr 2.

PMID:
18385277
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.

Ljung L, Askling J, Rantapää-Dahlqvist S, Jacobsson L; ARTIS Study Group.

Arthritis Res Ther. 2014 Jun 18;16(3):R127. doi: 10.1186/ar4584.

PMID:
24941916
[PubMed - in process]
Free PMC Article
10.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

PMID:
17049139
[PubMed - indexed for MEDLINE]
Free Article
11.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewé R.

Ann Rheum Dis. 2014 Mar;73(3):529-35. doi: 10.1136/annrheumdis-2013-204575. Epub 2014 Jan 8. Review.

PMID:
24401994
[PubMed - indexed for MEDLINE]
12.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

PMID:
16948890
[PubMed - indexed for MEDLINE]
Free Article
13.

Association between anti-TNF-α therapy and all-cause mortality.

Herrinton LJ, Liu L, Chen L, Harrold LR, Raebel MA, Curtis JR, Griffin MR, Solomon DH, Saag KG, Lewis JD.

Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1311-20. doi: 10.1002/pds.3354. Epub 2012 Oct 15.

PMID:
23065964
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewé R, Smolen JS, Emery P, Buch MH.

Ann Rheum Dis. 2010 Jun;69(6):976-86. doi: 10.1136/ard.2009.126573. Epub 2010 May 6. Review. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
20447957
[PubMed - indexed for MEDLINE]
15.

Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.

Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Kalstad S, Kaufmann C, Rødevand E, Kvien TK.

Ann Rheum Dis. 2011 Dec;70(12):2103-10. doi: 10.1136/ard.2011.152363. Epub 2011 Aug 28.

PMID:
21875874
[PubMed - indexed for MEDLINE]
16.

Tumor Necrosis Factor-α Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study.

Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski M, Farley J.

J Rheumatol. 2014 Aug 1. pii: jrheum.131464. [Epub ahead of print]

PMID:
25086079
[PubMed - as supplied by publisher]
17.

Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.

Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD; SABER Collaboration.

Arthritis Rheum. 2013 Jan;65(1):48-58. doi: 10.1002/art.37740.

PMID:
23055441
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.

Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, Kalstad S, Mikkelsen K, Kvien TK.

Ann Rheum Dis. 2014 Jan;73(1):132-7. doi: 10.1136/annrheumdis-2012-202347. Epub 2013 Jan 3.

PMID:
23291385
[PubMed - indexed for MEDLINE]
19.

Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis.

Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR.

Med Care. 2007 Oct;45(10 Supl 2):S66-76.

PMID:
17909386
[PubMed - indexed for MEDLINE]
20.

Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.

Aga AB, Lie E, Uhlig T, Olsen IC, Wierød A, Kalstad S, Rødevand E, Mikkelsen K, Kvien TK, Haavardsholm EA.

Ann Rheum Dis. 2013 Nov 27. doi: 10.1136/annrheumdis-2013-204020. [Epub ahead of print]

PMID:
24285493
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk